COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

D Baker, CAK Roberts, G Pryce, AS Kang… - Clinical & …, 2020 - academic.oup.com
Although most autoimmune diseases are considered to be CD4 T cell-or antibody-mediated,
many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma …

The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases

A DeMaio, S Mehrotra, K Sambamurti… - Journal of …, 2022 - Springer
The adaptive immune system and associated inflammation are vital in surveillance and host
protection against internal and external threats, but can secondarily damage host tissues …

Ocrelizumab: a review in multiple sclerosis

YN Lamb - Drugs, 2022 - Springer
Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

High-efficacy therapies for treatment-naïve individuals with relapsing–remitting multiple sclerosis

L Freeman, EE Longbrake, PK Coyle, B Hendin… - CNS drugs, 2022 - Springer
There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

B‐cell Therapy for Multiple Sclerosis: Entering an era

AL Greenfield, SL Hauser - Annals of neurology, 2018 - Wiley Online Library
Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …

Recent advances of nanotechnology application in autoimmune diseases–A bibliometric analysis

R He, L Li, T Zhang, X Ding, Y Xing, S Zhu, Z Gu, H Hu - Nano Today, 2023 - Elsevier
Autoimmune diseases are a group of serious immune system disorders that are usually
idiopathic and persistent. Currently, autoimmune diseases are often diagnosed after obvious …

The CD8 T cell-Epstein-Barr virus-B cell trialogue: a central issue in multiple sclerosis pathogenesis

C Veroni, F Aloisi - Frontiers in immunology, 2021 - frontiersin.org
The cause and the pathogenic mechanisms leading to multiple sclerosis (MS), a chronic
inflammatory disease of the central nervous system (CNS), are still under scrutiny. During …

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic

D Baker, S Amor, AS Kang, K Schmierer… - Multiple sclerosis and …, 2020 - Elsevier
Background SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute
respiratory distress syndrome (ARDS), which can cause significant mortality, leading to …

Tolerance in the age of immunotherapy

JA Bluestone, M Anderson - New England Journal of Medicine, 2020 - Mass Medical Soc
Immune Tolerance The immune system distinguishes between “self” and “nonself” and
remembers dangerous exposures. Elaborate mechanisms control immune responses, but in …

Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody …

JA Lopez, M Denkova, S Ramanathan… - Clinical & …, 2021 - Wiley Online Library
Autoimmunity plays a significant role in the pathogenesis of demyelination. Multiple
sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and myelin …